Investors areaInformation for investors Relevant information Press room Shareholders General Meetings
Vytrus increases its net profit by more than 100% in 2021
The biotechnology company has closed 2021 financial year with the best results in its history by rising its net profit by 100%. Vytrus also increased its market value by 100% in its first trading month.
Vytrus rises more than 25% in its stock market debut on March 15th
Vytrus Biotech has been listed in BME Growth and increases its market value by more than 25% in its first trading day.
Vytrus announces its intention to be listed in BME Growth and a 65% sales increase
The biotech company announces its intention to be listed in BME Growth in the coming months after having got a 65% in sales in 2021.
Vytrus increases its sales by 40% and triples its EBITDA in 2020.
Vytrus Biotech has broken its own record and turnover forecasts, reaching 1.7 million euros at the end of 2020. The company thus reaches a milestone in its trajectory: the operational break even.
Vytrus Biotech raises €1.7M and turns into an industrial company.
The Spanish biotech company, specialised in active ingredients for the cosmetic sector, reaches €1.22M on sales and expects to increase its turnover by 23% in 2020.